News

AC Immune will use a new $500,000 grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance the development of its ACI-12589 positron emission tomography (PET) scan tracer for the detection of alpha-synuclein protein — whose damaging clumps are a hallmark of Parkinson’s disease. The…

Using a newly created probe and non-invasive PET scans, researchers were able to visualize sites of alpha-synuclein protein clumps — associated with nerve damage in Parkinson’s disease — in the brains of living patients, scientists reported. This method may help in diagnosing conditions related to alpha-synuclein clumping, referred to…

SynAgile announced the completion of a Phase 2 clinical trial evaluating DopaFuse, its noninvasive system for the continuous oral delivery of levodopa/carbidopa to people with Parkinson’s disease. Sixteen adults being treated with levodopa/carbidopa (LD/CD) in a tablet form were enrolled in the open-label study into the safety and tolerability…

Alpha-synuclein aggregation — the toxic clumping of proteins in nerve cells that is a hallmark of Parkinson’s disease — starts on the membranes of mitochondria, the so-called powerhouse of a cell, according to work in cell models. “Our study provides insights into what is happening in the earliest stages…

Amneal Pharmaceuticals is seeking U.S. approval of IPX-203, its extended-release carbidopa-levodopa (CD/LD) tablets, for Parkinson’s disease. The company submitted an Investigational New Drug Application to the Food and Drug Administration (FDA), which is based on top-line data from the Phase 3 RISE-PD clinical trial that showed IPX-203…

A dozen runners who live with Parkinson’s disease (PD) hope to heighten awareness of the neurodegenerative disorder and raise funds for research by taking on one of the nation’s most demanding relay road races — the Blue Ridge Relay — on Sept. 9-10. The 12 runners, who’ve dubbed themselves…

Screening a large database with machine learning tools helped scientists identify approved medicines for other diseases that reduced the risk of developing Parkinson’s, a study reported. According to researchers, these potential Parkinson’s disease therapies “deserve to be confirmed” in larger studies. “Drug repurposing or repositioning is the application of…

In-home, non-contact sensors that can identify changes in movement and behaviors may allow age-related diseases, including Parkinson’s, to be detected early, a study reports. By using machine learning tools, the study shows how outcomes such as fall risk, frailty, and cognitive abilities may be assessed in a home setting.

Mirapex (pramipexole) improved the quality of life for people with Parkinson’s disease compared to a placebo, according to a pooled analysis of several clinical trials. Quality of life improvements were seen regardless of disease stage, duration of treatment, or quality of life assessments before treatment. This analysis provided new…

In a webinar hosted by AC Immune, scientists discussed the various advantages of vaccines — ranging from their expected safety and long-lasting immune responses to potentially lower costs — in treating and possibly preventing Parkinson’s and Alzheimer’s disease. The “Key Opinion Leader” webinar, broadcasted on Aug.